Targeting a specific genetic mutation to reduce lung cancer spread
Targeting SNP BRMS1v2 A273V/A273V to reduce metastases in lung adenocarcinoma
This study is looking at a specific genetic change in the BRMS1 gene that might help us understand how lung cancer spreads, with the hope of creating new treatments to stop this from happening in people with early-stage lung cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10672461 on NIH RePORTER |
What this research studies
This research investigates the role of a genetic mutation in the BRMS1 gene that is linked to the spread of lung adenocarcinoma. By understanding how the A273V mutation affects cancer cell behavior, the research aims to develop innovative therapies that could prevent metastasis in patients with early-stage lung cancer. The approach includes using advanced genetic sequencing and in vitro models to explore the mechanisms behind this mutation and its impact on cancer progression. The ultimate goal is to provide new treatment options for patients at risk of metastasis.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with early-stage lung adenocarcinoma who have the BRMS1v2 A273V mutation.
Not a fit: Patients with advanced lung cancer or those without the specific BRMS1v2 A273V mutation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly reduce the risk of lung cancer metastasis, improving survival rates for patients.
How similar studies have performed: Previous research has shown promising results in targeting genetic mutations to inhibit cancer metastasis, suggesting that this approach could be effective.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Jones, David R — Sloan-Kettering Inst Can Research
- Study coordinator: Jones, David R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.